GO:1903753 negative regulation of p38MAPK cascade: Signaling Brake, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903753 describes any process that stops, prevents, or reduces the frequency, rate, or extent of the p38MAPK cascade.
• The p38MAPK cascade is a stress-activated MAPK pathway; its negative regulation is critical for preventing excessive inflammation, cardiac stress responses, and aberrant proliferation.
• Key negative regulators include NBL1, which blocks PDGFβ-p38MAPK signaling in pulmonary artery smooth muscle cells, and Rac1, which modulates p38 activation in cardiac myocytes.
• Dysregulation of p38MAPK negative regulation is implicated in liver fibrosis, ischemic stroke, and cardiac pathology.
• Experimental models for studying this process include knockout, point-mutation, knock-in, and overexpression cell lines, as well as CRISPR library screening.
• Bioinformatics and genome-wide methylation analyses have identified Il1r2 and Tnfrsf12a as potential upstream regulators linked to p38MAPK negative regulation in stroke.
Description
The p38MAPK cascade is a central signaling module that converts extracellular stress stimuli into cellular responses such as inflammation, apoptosis, and differentiation. Unchecked p38MAPK activity contributes to tissue damage, chronic inflammation, and pathological remodeling, making its negative regulation a critical homeostatic mechanism. GO:1903753, negative regulation of p38MAPK cascade, captures the diverse molecular events that attenuate this pathway. Understanding this term is essential for researchers dissecting stress-response circuits, inflammatory diseases, and cardiac pathology. Recent studies have identified negative regulators such as NBL1, which inhibits PDGF-BB-induced p38MAPK activation in human pulmonary artery smooth muscle cells, and Rac1, which modulates p38 in cardiac myocytes. Additionally, bioinformatics analyses of ischemic stroke and liver fibrosis have highlighted genes like Il1r2 and Tnfrsf12a as potential components of p38MAPK negative regulation. This article provides a research-grade overview of GO:1903753, integrating authoritative QuickGO definitions with verified PubMed literature to support experimental design and therapeutic targeting.
negative regulation of p38MAPK cascade At A Glance
| GO ID | GO:1903753 |
|---|---|
| GO term | negative regulation of p38MAPK cascade |
| Ontology | biological_process |
| Synonym | inhibition of p38 MAPK cascade; down-regulation of p38 cascade; negative regulation of osmosensory signaling MAPK cascade |
| Major function | Attenuation of p38MAPK signaling to prevent excessive inflammatory, apoptotic, or hypertrophic responses |
| Related pathways | p38MAPK cascade, stress-activated protein kinase signaling, PDGFβ signaling |
| Key regulators | NBL1, Rac1, Il1r2, Tnfrsf12a (as identified in cited studies) |
| Disease relevance | Cardiac pathology, liver fibrosis, ischemic stroke, viral infections |
What Is GO:1903753?
GO:1903753, negative regulation of p38MAPK cascade, is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of the p38MAPK cascade. This biological process encompasses molecular brakes that act at various nodes of the p38MAPK signaling module, including inhibition of upstream activators, dephosphorylation of p38MAPK, or sequestration of pathway components. It is distinct from positive regulation and is essential for balancing stress-induced signaling.
Why Is negative regulation of p38MAPK cascade Important in Cell Biology?
Negative regulation of the p38MAPK cascade is vital because p38MAPK is a stress-responsive pathway that, when hyperactivated, drives chronic inflammation, cardiac hypertrophy, and fibrosis. The identification of negative regulators such as NBL1, which blocks PDGFβ-p38MAPK signaling in pulmonary artery smooth muscle cells, and Rac1, which modulates p38 in cardiac myocytes, underscores the therapeutic potential of targeting this process. Moreover, genome-wide studies in liver fibrosis and ischemic stroke have linked DNA methylation dynamics and gene expression changes to p38MAPK-related negative regulation. Understanding GO:1903753 therefore provides a framework for developing interventions that restore pathway balance in disease.
• Prevents excessive inflammation by dampening p38MAPK-driven cytokine production.
• Protects against cardiac hypertrophy and heart failure by limiting stress-activated MAPK signaling.
• Modulates pulmonary artery smooth muscle cell proliferation, with implications for pulmonary hypertension.
• Influences liver fibrosis progression through epigenetic regulation of p38MAPK-related genes.
• Plays a role in ischemic stroke recovery, as suggested by bioinformatics analysis of Il1r2 and Tnfrsf12a.
• Contributes to host response to viral infections by shaping MAPK signaling signatures.
• Provides a target for therapeutic intervention in inflammatory and fibrotic diseases.
• Helps maintain cellular homeostasis by preventing apoptosis and senescence induced by sustained p38MAPK activity.
• Is essential for proper cell cycle regulation, as p38MAPK negatively regulates cyclin D1 expression.
• Offers a basis for CRISPR-based screens to identify novel negative regulators.
What Happens During negative regulation of p38MAPK cascade?
Initiation of negative feedback
In simple terms: The cell senses too much p38MAPK activity and starts to put the brakes on.
Negative regulation of the p38MAPK cascade can be initiated by extracellular cues or intracellular stress that trigger feedback loops. For example, NBL1 inhibits PDGF-BB-induced p38MAPK activation in human pulmonary artery smooth muscle cells, blocking the PDGFβ-p38MAPK pathway. Similarly, Rac1 acts as a modulator of p38 in cardiac myocytes, where its activation can lead to negative regulation of the cascade under certain conditions.
Attenuation of upstream activators
In simple terms: Proteins that normally turn on p38 are themselves turned off or blocked.
Negative regulation often involves interference with upstream kinases or adaptor proteins. For instance, the inhibition of PDGFβ signaling by NBL1 prevents the activation of downstream p38MAPK. In cardiac myocytes, Rac1-mediated signaling can influence the activity of MAPK kinases, thereby reducing p38 phosphorylation. Additionally, bioinformatics analyses have identified Il1r2 and Tnfrsf12a as potential negative regulators in ischemic stroke, possibly by modulating upstream inflammatory signaling.
Dephosphorylation of p38MAPK
In simple terms: Phosphate groups are removed from p38, switching it off.
Dual-specificity phosphatases (DUSPs) can directly dephosphorylate p38MAPK, terminating the signal. Although specific DUSPs are not detailed in the provided citations, the concept of phosphatase-mediated negative regulation is a well-established mechanism in MAPK cascades. The balance between kinases and phosphatases determines the duration and magnitude of p38MAPK signaling.
Cross-talk with other pathways
In simple terms: Other signaling pathways can interfere with p38 to shut it down.
Negative regulation can occur through cross-talk with other MAPK pathways. For example, isoform-specific optical activation of kinase function has revealed p38-ERK signaling crosstalk, where ERK activation can negatively regulate p38 activity. This interplay ensures that cellular responses are appropriately coordinated.
Transcriptional and epigenetic control
In simple terms: The cell can change gene expression to reduce p38 signaling over time.
Long-term negative regulation involves transcriptional and epigenetic changes. Genome-wide DNA methylation dynamics in carbon tetrachloride-induced liver fibrosis have been linked to altered expression of genes in the p38MAPK pathway, suggesting epigenetic control of negative regulators. Similarly, host response to viral infections reveals common and virus-specific signatures that may include negative regulators of p38MAPK.
Key Genes Involved in GO:1903753 negative regulation of p38MAPK cascade
The following genes and proteins have been experimentally or computationally linked to negative regulation of the p38MAPK cascade in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NBL1 | Inhibits PDGF-BB-induced p38MAPK activation in PASMC | Potential therapeutic target for pulmonary hypertension |
| Rac1 | Modulates p38MAPK in cardiac myocytes | Implicated in cardiac hypertrophy and failure |
| Il1r2 | Decoy receptor for IL-1, may dampen p38MAPK signaling | Identified in ischemic stroke bioinformatics |
| Tnfrsf12a | Receptor for TWEAK, can modulate MAPK pathways | Linked to stroke recovery in bioinformatics |
| DUSP1 | Dual-specificity phosphatase, dephosphorylates p38MAPK | Broad negative regulator of MAPK cascades |
| DUSP10 | Dephosphorylates p38MAPK and JNK | Potential tumor suppressor |
| Cyclin D1 | Negatively regulated by p38MAPK pathway | Cell cycle control |
| MAPK14 | p38α isoform, substrate of negative regulation | Central node in stress signaling |
| MAPK11 | p38β isoform | Isoform-specific regulation |
| MAPK12 | p38γ isoform | Tissue-specific functions |
| MAPK13 | p38δ isoform | Isoform-specific negative regulation |
| PDGFB | Upstream activator of p38MAPK | Target of NBL1 inhibition |
| IL1B | Pro-inflammatory cytokine activating p38MAPK | Negative regulation limits inflammation |
| TNF | Activates p38MAPK | Negative regulation in viral infections |
| RAC1 | Small GTPase, modulator of p38 | Cardiac myocyte signaling |
| HSPB1 | Heat shock protein, downstream of p38 | Readout of pathway activity |
| ATF2 | Transcription factor activated by p38 | Downstream effector |
How Is negative regulation of p38MAPK cascade Regulated?
Negative regulation of the p38MAPK cascade is itself tightly controlled. Upstream signals such as growth factors (e.g., PDGF-BB) can be blocked by inhibitors like NBL1. Small GTPases such as Rac1 modulate the pathway in a cell-type-specific manner. Cross-talk with ERK signaling can attenuate p38 activity. Additionally, epigenetic mechanisms, including DNA methylation, can alter the expression of negative regulators in conditions like liver fibrosis. Viral infections can also induce host response signatures that include negative regulators of p38MAPK.
negative regulation of p38MAPK cascade and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NBL1 | Pulmonary hypertension | Knockout of NBL1 in PASMC, overexpression in KO background |
| Rac1 | Cardiac hypertrophy | Cardiac-specific Rac1 knockout or point mutation |
| Il1r2 | Ischemic stroke | Knock-in of human variant in mouse stroke model |
| Tnfrsf12a | Ischemic stroke | Overexpression in neuronal cells |
| DUSP1 | Inflammatory diseases | Knockout in macrophages, overexpression in fibroblasts |
Cardiac pathology
Dysregulation of p38MAPK negative regulation contributes to cardiac hypertrophy and heart failure. Rac1-mediated modulation of p38 in cardiac myocytes is critical for maintaining cardiac homeostasis, and its perturbation leads to pathological remodeling. Mitogen-activated protein kinases, including p38, are considered therapeutic targets in cardiac pathology.
Liver fibrosis
Genome-wide DNA methylation dynamics in carbon tetrachloride-induced liver fibrosis suggest that epigenetic silencing of negative regulators of p38MAPK may promote fibrogenesis. This highlights the importance of negative regulation in chronic liver disease.
Ischemic stroke
Bioinformatics analysis of transcranial magnetic stimulation in ischemic stroke identified Il1r2 and Tnfrsf12a as potential genes involved in negative regulation of p38MAPK, offering new avenues for stroke therapy.
Viral infections
The host response to viral infections reveals common and virus-specific signatures in peripheral blood, which may include negative regulators of p38MAPK that shape the inflammatory response.
From negative regulation of p38MAPK cascade-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does NBL1 inhibit p38MAPK in PASMC? | NBL1 knockout and overexpression in human PASMC |
| How does Rac1 modulate p38 in cardiac myocytes? | Rac1 point mutation (constitutively active/dominant negative) in cardiomyocytes |
| What is the role of Il1r2 in stroke recovery? | Il1r2 knockout mouse subjected to MCAO |
| Can epigenetic silencing of DUSP1 promote fibrosis? | DUSP1 promoter methylation knock-in in hepatocytes |
| What is the effect of p38-ERK crosstalk? | Optogenetic activation of p38 and ERK in cell lines |
| Which genes negatively regulate p38 in viral infection? | CRISPR library screening in infected cells |
How to Study the negative regulation of p38MAPK cascade Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Western blot | Phospho-p38 levels | Validation of negative regulation in cell lines |
| RNA-seq | Transcriptomic changes | Identification of pathways affected by negative regulators |
| Methylation array | DNA methylation status | Epigenetic regulation in fibrosis |
| CRISPR screen | Gene knockout effects on p38 activity | Discovery of novel negative regulators |
| Optogenetics | Real-time kinase activity | Studying p38-ERK crosstalk |
| Bioinformatics | Gene expression signatures | Predicting upstream regulators in disease |
| Phospho-proteomics | Global phosphorylation changes | Mapping downstream targets |
| Immunofluorescence | Subcellular localization of p38 | Visualizing pathway activation |
Phospho-proteomics
Phospho-proteomics can quantify changes in p38MAPK phosphorylation and identify downstream substrates. This method is useful for assessing the impact of negative regulators like NBL1 or Rac1 on pathway activity.
RNA-seq and bioinformatics
RNA-seq combined with bioinformatics analysis can reveal gene expression signatures associated with negative regulation of p38MAPK, as demonstrated in ischemic stroke and viral infection studies.
Genome-wide methylation profiling
DNA methylation arrays can identify epigenetic changes in genes related to p38MAPK negative regulation, as shown in liver fibrosis models.
Optogenetic kinase control
Isoform-specific optical activation of kinases allows precise manipulation of p38 and ERK signaling to study crosstalk and negative regulation in real time.
How CRISPR Can Be Used to Study GO:1903753 negative regulation of p38MAPK cascade
Knockout
CRISPR knockout of candidate negative regulators (e.g., NBL1, DUSP1) can confirm their role in attenuating p38MAPK signaling. For example, NBL1 knockout in PASMC would be expected to enhance PDGF-BB-induced p38 activation.
Point Mutation
Point mutations can be introduced to mimic constitutively active or inactive forms of regulators like Rac1, allowing precise dissection of their role in p38 negative regulation.
Knock-in
Knock-in of disease-associated variants (e.g., in Il1r2 or Tnfrsf12a) can model their impact on p38MAPK negative regulation in relevant cell types.
Overexpression
Overexpression of negative regulators such as NBL1 or DUSP1 can suppress p38MAPK activity and rescue pathological phenotypes, providing proof-of-concept for therapeutic targeting.
How EDITGENE Supports negative regulation of p38MAPK cascade Research
Researchers studying negative regulation of p38MAPK cascade-related genes often need to determine whether a candidate gene is causally involved in attenuating the pathway. EDITGENE provides a comprehensive suite of CRISPR services to enable such functional studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of p38MAPK cascade research.
Frequently Asked Questions About negative regulation of p38MAPK cascade
What is negative regulation of p38MAPK cascade?
It is any process that stops, prevents, or reduces the frequency, rate, or extent of the p38MAPK cascade, as defined by GO:1903753.
What genes are involved in negative regulation of p38MAPK cascade?
Key genes include NBL1, Rac1, Il1r2, Tnfrsf12a, and DUSPs, as identified in various studies.
How does NBL1 inhibit p38MAPK?
NBL1 blocks PDGF-BB-induced p38MAPK activation in human pulmonary artery smooth muscle cells.
What is the role of Rac1 in p38MAPK negative regulation?
Rac1 modulates p38MAPK activity in cardiac myocytes, contributing to negative regulation under certain conditions.
Which diseases are linked to dysregulated p38MAPK negative regulation?
Cardiac pathology, liver fibrosis, ischemic stroke, and viral infections have been associated with altered negative regulation.
How can CRISPR be used to study negative regulation of p38MAPK cascade?
CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect gene function in this pathway.
What methods are used to measure p38MAPK negative regulation?
Western blot for phospho-p38, RNA-seq, methylation arrays, and optogenetics are commonly used.
Is p38MAPK negative regulation a therapeutic target?
Yes, targeting negative regulators could treat inflammatory and cardiac diseases.
What is the GO ID for negative regulation of p38MAPK cascade?
GO:1903753.
What are synonyms for negative regulation of p38MAPK cascade?
Synonyms include inhibition of p38 MAPK cascade, down-regulation of p38 cascade, and negative regulation of osmosensory signaling MAPK cascade.
Conclusion
GO:1903753, negative regulation of p38MAPK cascade, is a critical biological process that maintains cellular homeostasis by attenuating stress-induced signaling. The identification of negative regulators such as NBL1 and Rac1, along with bioinformatics insights from stroke and fibrosis studies, highlights its broad relevance to human disease. Leveraging CRISPR-based models and multi-omics approaches will further elucidate these mechanisms and facilitate therapeutic development.
References
- 1. Cui C et al.. 2016. Inhibitory effect of NBL1 on PDGF-BB-induced human PASMC proliferation through blockade of PDGFβ-p38MAPK pathway.. Biosci Rep 36(4) PMID: 27474499
- 2. Zhao M et al.. 2024. Il1r2 and Tnfrsf12a in transcranial magnetic stimulation effect of ischemic stroke via bioinformatics analysis.. Medicine (Baltimore) 103(4):e36109 PMID: 38277520
- 3. Clerk A et al.. 2001. Regulation of mitogen-activated protein kinases in cardiac myocytes through the small G protein Rac1.. Mol Cell Biol 21(4):1173-84 PMID: 11158304
- 4. Li D et al.. 2023. Genome-wide DNA methylation dynamics in carbon tetrachloride-induced mice liver fibrosis.. Iran J Basic Med Sci 26(1):85-92 PMID: 36594057
- 5. Tsalik EL et al.. 2021. The Host Response to Viral Infections Reveals Common and Virus-Specific Signatures in the Peripheral Blood.. Front Immunol 12:741837 PMID: 34777354
- 6. Zhou W et al.. 2023. Isoform-specific optical activation of kinase function reveals p38-ERK signaling crosstalk.. RSC Chem Biol 4(10):765-773 PMID: 37799579
- 7. Ravingerová T et al.. 2003. Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology.. Mol Cell Biochem 247(1-2):127-38 PMID: 12841640
- 8. Lavoie JN et al.. 1996. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway.. J Biol Chem 271(34):20608-16 PMID: 8702807
